Technical Reports on Drug Delivery Equities -- PetMed Express, Adamis Pharma, Delcath Systems, and Alkermes

Friday, July 14, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 14, 2017 /PRNewswire/ --

If you want a Stock Review on PETS, ADMP, DCTH or ALKS then come over to and sign up for your free customized report today. Today's research on is focused on Drug Delivery companies, which market and ship prescription and non-prescription medications for human
and animal use, along with other health products. These companies are generally structured as corporations and offer higher-than-average dividend yields. Under scanner this morning are: PetMed Express Inc. (NASDAQ: PETS), Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), Delcath Systems Inc. (NASDAQ: DCTH), and Alkermes PLC (NASDAQ: ALKS). Learn more about these stocks by downloading their comprehensive and free reports from member's area at:

PetMed Express 

On Thursday, shares in Delray Beach, Florida headquartered PetMed Express Inc. climbed 0.43%, ending the day at $40.02. The stock recorded a trading volume of 377,277 shares. The Company's shares have advanced 9.91% in the last one month, 87.27% over the previous three months, and 73.47% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 11.60% and 60.19%, respectively. Moreover, shares of PetMed Express, which operates as a pet pharmacy in the US, have a Relative Strength Index (RSI) of 56.28. PETS complete research report is just a click away at:

Adamis Pharma 

Shares in San Diego, California headquartered Adamis Pharmaceuticals Corp. ended the day 1.83% lower at $5.35 with a total trading volume of 355,356 shares. In the last month and the previous three months, the stock has gained 27.38% and 18.89%, respectively. Additionally, the Company's shares have surged 69.84% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 20.55% and 46.85%, respectively. Furthermore, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have an RSI of 57.14.  

On June 15th, 2017, Adamis Pharmaceuticals announced that the US Food and Drug Administration ("FDA") has approved its EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) ("PFS") for the emergency treatment of allergic reactions (Type I) including anaphylaxis. The FDA has also approved the PFS trade name of Symjepi™. The complimentary report on ADMP can be downloaded at:

Delcath Systems 

At the close of trading on Thursday, shares in New York headquartered Delcath Systems Inc. finished 14.72% lower at $0.14 with a total trading volume of 66.65 million shares. The stock has skyrocketed 171.48% in the last one month and 123.47% over the previous three months. The Company's shares are trading above their 50-day moving average by 55.96%. Additionally, shares of Delcath Systems, which focuses on the treatment of primary and metastatic liver cancers, has an RSI of 49.41. Sign up for your complimentary research report on DCTH at:


Dublin, Ireland headquartered Alkermes PLC's shares recorded a trading volume of 635,854 shares at the end of yesterday's session. The stock closed the day 1.59% higher at $58.79. The Company's shares have advanced 0.31% in the past month, 3.23% in the previous three months, and 5.78% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.51% and 5.02%, respectively. Additionally, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide, have an RSI of 51.07.

On June 29th, 2017, Alkermes announced positive preliminary top-line results from ENLIGHTEN-1, the first of two key phase-3 studies in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia. The positive results of ENLIGHTEN-1 provide clear evidence of the safety, tolerability, and antipsychotic efficacy of ALKS 3831 in a large, randomized registration trial. Get free access to your research report on ALKS at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:(207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store